Infinity Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-12-26: Form 8-K; Period of report 2012-12-24; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2012-12-13: Form 8-K; Period of report 2012-12-13; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2012-12-12: Form 8-K; Period of report 2012-12-12; Description 8.01 Other Events; Details 8.01.
- 2012-12-10: Form 8-K; Period of report 2012-12-10; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-12-26 | 8-K | 2012-12-24 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 In July 2010, we entered into a development and license agreement with Intellikine, Inc., or Intellikine, under which we obtained rights under Intellikine intellectual property to discover, develop and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of phosphoinositide-3-kinase, or PI3K, including IPI-145. 8.01 We issued a press release on December 24, 2012, announcing the execution of the amended and restated development and license agreement with Intellikine LLC. | d458757d8k.htm |
| 2012-12-13 | 8-K | 2012-12-13 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On December 13, 2012, Infinity Pharmaceuticals, Inc. (“we,” “us” or “our”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC acting as representatives of the underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering of 5,696,923 shares (the “Shares”) of our common stock, par value $0.001 per share (the “Common Stock”). 8.01 We issued a press release on December 13, 2012 announcing the pricing of the public offering. | d452728d8k.htm |
| 2012-12-12 | 8-K | 2012-12-12 | 8.01 Other Events | 8.01 The Company is filing the risk factors attached hereto as Exhibit 99.1 for the purpose of updating and superseding the risk factor disclosure contained in its public filings, including those discussed under the caption “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2011, which was filed with the SEC on March 13, 2012 and its Quarterly Report on Form 10-Q for the period ended September 30, 2012, which was filed with the SEC on November 6, 2012. | d452166d8k.htm |
| 2012-12-10 | 8-K | 2012-12-10 | 8.01 Other Events | 8.01 On December 10, 2012, we announced new data from our ongoing Phase 1, open-label, dose-escalation trial of IPI-145, our potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies. | d451707d8k.htm |
| 2012-11-06 | 8-K | 2012-11-02 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 On November 6, 2012, we issued a press release announcing our results for the quarter ended September 30, 2012 and will conduct a previously-announced, publicly-available conference call to discuss those results. 5.02 (b) On November 2, 2012 Steven H. Holtzman, the Chair of our Board of Directors (the “Board”) notified the Board of his decision to resign from our Board effective immediately. 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. 8.01 The information in Item 5.02 is incorporated by reference into this Item 8.01. | d433419d8k.htm |
| 2012-08-14 | 8-K | 2012-08-14 | 7.01 Regulation FD Disclosure | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. | d395797d8k.htm |
| 2012-08-10 | 8-K | 2012-08-09 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On August 9, 2012, we entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC acting as representatives of the underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering of 5,300,000 shares (the “Shares”) of our common stock, par value $0.001 per share (the “Common Stock”). 8.01 We issued a press release on August 9, 2012 announcing the pricing of the public offering. | d393880d8k.htm |
| 2012-08-07 | 8-K | 2012-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2012, we issued a press release announcing our results for the quarter ended June 30, 2012 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d392677d8k.htm |
| 2012-07-25 | 8-K | 2012-07-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (c) We executed an offer letter with Lawrence E. Bloch, M.D., J.D., age 47, governing the terms of Dr. Bloch’s employment as our Executive Vice President, Chief Financial Officer and Chief Business Officer for an indefinite term. | d385059d8k.htm |
| 2012-07-19 | 8-K | 2012-07-17 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 On July 17, 2012, we entered into Termination and Revised Relationship Agreements (the “Termination and Revised Relationship Agreements”) with Mundipharma International Corporation Limited (“Mundipharma”) and Purdue Pharmaceutical Products L.P. (“Purdue”). 1.02 On November 19, 2008, we entered into a strategic alliance with Mundipharma and Purdue to develop and commercialize pharmaceutical products. 3.02 The information set forth in Item 1.01 above under the caption “Securities Purchase Agreement” is incorporated herein by reference. 8.01 On July 18, 2012, we issued a press release announcing the transactions described in this report. | d384770d8k.htm |
| 2012-07-17 | 8-K | 2012-07-16 | 8.01 Other Events | 8.01 On July 2, 2012, Infinity Pharmaceuticals, Inc. (the “Company”) reported that it had agreed to a request made by Mundipharma International Corporation Limited (“Mundipharma”) to delay the due date for payment by Mundipharma of the 2012 third quarter invoice for research and development funding due under the strategic alliance agreement between the Company and Mundipharma, in the amount of $27.5 million, until July 16, 2012. | d381411d8k.htm |
| 2012-07-02 | 8-K | 2012-07-01 | 8.01 Other Events | 8.01 In November 2008, Infinity Pharmaceuticals, Inc. (the “Company”) entered into a strategic alliance with Mundipharma International Corporation Limited (“Mundipharma”) and Purdue Pharmaceutical Products L.P. (“Purdue”) to develop and commercialize pharmaceutical products. | d376180d8k.htm |
| 2012-06-18 | 8-K | 2012-06-18 | 8.01 Other Events | 8.01 On June 18, 2012, we announced that we have voluntarily stopped our Phase 2 clinical trials evaluating saridegib (also known as IPI-926) in patients with chondrosarcoma and myelofibrosis. | d368968d8k.htm |
| 2012-05-18 | 8-K | 2012-05-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 At our Annual Meeting of stockholders held on May 16, 2012 (the “Annual Meeting”), our stockholders approved Amendment No. 2 to our 2010 Stock Incentive Plan (the “2010 Plan”), which amendment had previously been adopted by our Board of Directors, subject to shareholder approval, to increase the number of shares of our common stock that may be issued pursuant to awards granted under the 2010 Plan by an additional 3,000,000 shares. | d356321d8k.htm |
| 2012-05-08 | 8-K | 2012-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2012, we issued a press release announcing our results for the quarter ended March 31, 2012 and will conduct a previously announced, publicly available conference call to discuss those results. | d348690d8k.htm |
| 2012-04-20 | 8-K | 2012-04-20 | 7.01 Regulation FD Disclosure | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. | d338118d8k.htm |
| 2012-03-13 | 8-K | 2012-03-08 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On March 13, 2012, we issued a press release announcing our results for the year ended December 31, 2011 and will conduct a previously announced, publicly available conference call to discuss those results. 5.02 (b) On March 8, 2012, James B. Tananbaum, M.D. and Arnold J. Levine, Ph.D. informed our company that they will not stand for re-election to our Board of Directors (the “Board”) at our 2012 annual meeting of stockholders. | d314505d8k.htm |
| 2012-01-27 | 8-K | 2012-01-27 | 8.01 Other Events | 8.01 On January 27, 2012, we announced that we have voluntarily stopped our Phase 2 clinical trial of saridegib (also known as IPI-926) plus gemcitabine in patients with metastatic pancreatic cancer. | d290658d8k.htm |
| 2012-01-09 | 8-K | 2012-01-04 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. 8.01 On January 4, 2012, we issued a press release announcing our 2012 business goals and financial guidance. | d279140d8k.htm |